🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Merck & Co., Inc. MRK SPXR3KPHARMA

Healthcare · Drug Manufacturers - General · United States
https://www.merck.com
Company Profile ↓
$150.33
+87.83% 1Y
Mkt Cap$371.29B
P/E120.26
P/B6.92
Div. Yield2.65%
52W High$156.45
52W Low$75.83
Book Value$18.58
EPS (TTM)$1.25

Company Overview

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 34.7%, reflecting efficient use of shareholder capital.

Consistent Profit Growth

Net profit has compounded at 10.0% per year over the last five years.

Dividend Income

Offers a dividend yield of 2.65%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $65.01B (+1.3% YoY); net profit $18.25B.
  • Trailing 12 Months Year-on-year growth — revenue +5.1%, earnings +6.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 5.6%, profit CAGR 10.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:5.64%
1 Year:5.10%

Compounded Profit Growth

5 Years:10.01%
1 Year:6.64%

Stock Price Performance

1 Year:+87.83%
6 Months:+31.73%
3 Months:+25.35%
1 Month:+17.11%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 92% of range
$75.83 $156.45
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)62.30 · Neutral
Price Performance
1M+17.11%
3M+25.35%
6M+31.73%
1Y+87.83%
Valuation vs Sector

P/E of 120.26 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 34.7%.
  • Profit CAGR of 10.0% over 5 years.
  • Attractive dividend yield of 2.65%.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 120.3.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
120.26
Industry PE
25.17
Forward P/E
15.66
PEG Ratio
12.28
Book Value
$18.58
Price to Book
6.92
P/S
4.77
EV/EBITDA
23.79
Dividend Yield
2.65%

Growth (CAGR)

Revenue 5Y
5.64%
Profit 5Y
10.01%
Revenue (YoY)
5.10%
Earnings (YoY)
6.64%

Profitability & Returns

ROCE
-
ROE
34.70%
ROA
13.34%
Profit Margin
4.77%
Op Margin
-1.37%
Gross Margin
75.95%
EPS (Latest Qtr)
$-0.54
EPS (TTM)
$1.25

Balance Sheet & Liquidity

Debt/Equity
1.07
Quick Ratio
-
Current Ratio
-
Debt
$49.12B
Total Assets
$129.80B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
0.06%
Chg in Prom Hold
-0.00%
FII / Inst Holding
82.71%
Chg in FII Hold
-0.02%

Financial Snapshot

Enterprise Value
$371.29B
Total Revenue (TTM)
$66.57B
EBITDA
$15.18B
Free Cash Flow
$12.36B
Operating Cash Flow
$16.47B
Shares Outstanding
2.47B
Gross Margin
75.95%
Payout Ratio
268.80%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
6 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
7 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
8 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 608.52 32.79 $225.00B 0.32% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2013Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue ------------9.93B10.32B10.04B10.46B10.79B10.82B11.76B12.40B12.06B9.35B10.93B10.63B11.40B13.15B15.90B14.59B14.96B14.49B15.04B15.96B15.78B16.11B16.66B15.53B15.81B17.28B16.29B16.61B
Net Income 906.00M1.12B1.71B2.00B895.00M953.00M687.00M1.83B1.12B1.21B2.18B1.55B1.95B-56.00M736.00M1.71B1.95B2.92B2.67B1.90B3.22B3.00B2.94B3.18B1.54B4.57B4.31B3.94B3.25B2.82B-5.97B4.75B4.76B5.46B3.16B5.08B4.43B5.79B-4.24B-1.33B
Diluted EPS 0.300.380.570.680.310.330.240.640.400.430.780.560.71-0.020.270.630.731.121.030.741.261.181.161.250.611.801.701.551.281.11-2.351.861.872.141.242.011.762.32-1.72-0.54
R&D Expense 2.10B1.66B1.57B1.66B1.66B1.74B1.67B1.50B1.66B2.15B1.66B1.83B1.78B4.41B3.20B2.27B2.07B1.93B2.19B3.20B2.21B2.08B3.35B2.41B4.32B2.44B2.58B2.80B4.40B4.28B13.32B3.31B3.99B3.50B5.86B3.62B4.05B4.23B12.59B9.74B

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 24.20B23.85B27.43B45.99B48.05B47.27B44.03B42.24B39.50B39.81B40.12B42.29B39.12B41.52B48.70B59.28B60.12B64.17B65.01B
Net Income 3.28B7.81B12.90B861.00M6.27B6.17B4.40B11.92B4.44B3.92B2.39B6.22B9.84B7.07B13.05B14.52B365.00M17.12B18.25B
Diluted EPS 1.493.635.650.282.022.001.474.071.561.410.872.323.812.785.145.710.146.747.28
R&D Expense 4.88B4.80B5.84B11.11B8.47B8.17B7.50B7.18B6.70B10.26B10.34B9.75B9.72B13.40B12.24B13.55B30.53B17.94B15.79B

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --47.20B112.31B105.78B105.13B106.13B105.64B98.17B101.68B95.38B87.87B82.64B84.40B91.59B105.69B109.16B106.67B117.11B136.87B
Total Equity 19.97B20.59B18.76B59.06B54.38B54.52B53.02B49.77B48.65B44.68B40.09B34.34B26.70B25.91B25.32B38.18B45.99B37.58B46.31B52.61B
Cash & Equivalents 5.91B5.34B4.37B9.31B10.90B13.53B13.45B15.62B7.44B8.52B6.51B6.09B7.96B9.68B8.05B8.10B12.69B6.84B13.24B14.56B
Long Term Debt --3.94B16.09B15.48B15.53B16.25B20.54B18.70B23.83B24.27B21.35B19.81B22.74B25.36B30.69B28.75B33.68B34.46B46.75B
Current Liabilities --14.32B15.64B15.64B16.25B18.35B17.87B18.40B19.20B17.20B18.61B22.21B22.22B27.33B23.87B24.24B25.69B28.42B28.33B

Cash Flows (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 7.00B6.57B3.39B10.82B12.38B10.02B11.65B7.99B12.54B10.38B6.45B10.92B13.44B10.25B-19.09B13.01B21.47B16.47B
Investing Cash Flow -2.81B-1.83B3.16B-3.50B-2.89B-6.80B-3.15B-374.00M-4.76B-3.21B2.68B4.31B-2.63B-9.44B--4.96B-14.08B-7.73B-13.74B
Financing Cash Flow -4.87B-5.52B-1.64B-5.44B-6.90B-3.27B-5.99B-15.24B-5.39B-9.04B-10.01B-13.16B-8.86B-2.83B--9.12B-4.81B-7.03B-1.92B
Capital Expenditure ---------------4.45B-4.39B-3.86B-3.37B-4.11B
Free Cash Flow ---------------14.71B9.14B18.10B12.36B
Share Buybacks 1.43B2.73B01.59B1.92B2.59B6.52B7.70B4.19B3.43B4.01B9.09B4.78B1.28B840.00M01.35B1.31B5.08B

Ratios (Annual)

Figures in %.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------------
Operating Margin % -------------------
Net Margin % 13.5%32.7%47.0%1.9%13.1%13.0%10.0%28.2%11.2%9.8%6.0%14.7%25.2%17.0%26.8%24.5%0.6%26.7%28.1%
ROE % 15.9%41.6%21.8%1.6%11.5%11.6%8.8%24.5%9.9%9.8%7.0%23.3%38.0%27.9%34.2%31.6%1.0%37.0%34.7%
ROCE % -------------------

Shareholding Pattern

Insiders
0.06%
Institutions
82.71%
Public Float
82.75%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 9.20% 227.00M $33.68B
2 Vanguard Capital Management LLC 6.54% 161.32M $23.93B
3 State Street Corporation 4.88% 120.41M $17.86B
4 Wellington Management Group, LLP 3.50% 86.25M $12.80B
5 Vanguard Portfolio Management LLC 2.75% 67.74M $10.05B
6 Geode Capital Management, LLC 2.46% 60.74M $9.01B
7 Charles Schwab Investment Management, Inc. 2.20% 54.37M $8.07B
8 Morgan Stanley 1.97% 48.64M $7.22B
9 FMR, LLC 1.84% 45.44M $6.74B
10 JPMORGAN CHASE & CO 1.78% 43.89M $6.51B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MRK

Yahoo Finance Mon, 07 Sep 2026

Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva

Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has b…

Yahoo Finance Fri, 04 Sep 2026

Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Merck (MRK) concluded the recent trading session at $150.32, signifying a -1.33% move from its prior day's close.

Yahoo Finance hu, 03 Sep 2026

Merck's $8.4 Billion Keytruda Fortress Gets a 2028 Warning

Cipla secured exclusive U.S. commercialization rights to Qilu's proposed biosimilar ahead of Keytruda's expected 2028 patent expiration.

Yahoo Finance hu, 03 Sep 2026

Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug

Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.

Yahoo Finance Mon, 07 Sep 2026

Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight

Emerging therapies for ulcerative colitis treatment, such as Obefazimod (Abivax), Tulisokibart (Merck), Olamkicept (Ferring Pharmaceuticals), Afimkibart (Roche), Icotrokinra (Johnson & Johnson/Protagonist Therapeutics), Duvakitug (Teva Phar…

Yahoo Finance hu, 03 Sep 2026

Moderna’s Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 44% Stock Drop

Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.

MRK — Frequently Asked Questions

What is the current share price of Merck & Co., Inc. (MRK)?

As of 2026-09-07 16:24 PDT, Merck & Co., Inc. (MRK) trades at $150.33 on NYSE. Its 52-week range is $75.83 to $156.45.

What is the market capitalisation of MRK?

Merck & Co., Inc. (MRK) has a market capitalisation of $371.29B on NYSE.

What is the P/E ratio of MRK?

MRK trades at a trailing price-to-earnings (P/E) ratio of 120.26. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 6.92.

Does MRK pay a dividend?

Merck & Co., Inc. (MRK) currently offers a dividend yield of 2.65%.

What is the return on equity (ROE) of MRK?

MRK has a return on equity (ROE) of 34.70%.

Is MRK a good stock to buy?

This page provides a data-driven analysis of Merck & Co., Inc. (MRK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space